461.93

3.80% 16.89

After Hours: 461.93

Madrigal Pharmaceuticals Inc (MDGL)

Overview News Price History Option Chain Financials Why MDGL Down? Discussions Forecast Stock Split

Madrigal Pharmaceuticals Inc stock is traded at $461.93, with a volume of 303.50K. It is up +3.80% in the last 24 hours and up +6.19% over the past month. Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Previous Close:

$445.04

Open:

$448.79

24h Volume:

303.50K

Relative Volume:

0.88

Market Cap:

$10.60B

Revenue:

$958.40M

Net Income/Loss:

$-288.28M

P/E Ratio:

-35.91

EPS:

-12.8641

Net Cash Flow:

$-193.02M

1W Performance:

+4.51%

1M Performance:

+6.19%

6M Performance:

+9.21%

1Y Performance:

+34.56%

1-Day Range:

$448.49

$471.72

1-Week Range:

$437.05

$471.72

52-Week Range:

$265.00

$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name

Madrigal Pharmaceuticals Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

404-380-9263

Address

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Employee

915

Twitter

@MadrigalPharma

Next Earnings Date

2024-10-31

Latest SEC Filings

MDGL's Discussions on Twitter

Compare MDGL vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MDGL Madrigal Pharmaceuticals Inc	461.93	10.21B	958.40M	-288.28M	-193.02M	-12.86
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Initiated	Barclays	Overweight
Jan-06-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-05-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-03-25	Upgrade	BofA Securities	Underperform → Neutral
Oct-15-25	Initiated	Truist	Buy
Sep-04-25	Resumed	H.C. Wainwright	Buy
Feb-28-25	Upgrade	B. Riley Securities	Neutral → Buy
Feb-27-25	Reiterated	H.C. Wainwright	Buy
Jun-28-24	Initiated	Cantor Fitzgerald	Neutral
Jun-11-24	Initiated	Wolfe Research	Outperform
Apr-22-24	Initiated	BofA Securities	Underperform
Mar-15-24	Upgrade	B. Riley Securities	Sell → Neutral
Mar-06-24	Initiated	Citigroup	Buy
Feb-26-24	Downgrade	B. Riley Securities	Neutral → Sell
Dec-20-22	Reiterated	Oppenheimer	Outperform
Dec-19-22	Reiterated	H.C. Wainwright	Buy
Dec-19-22	Reiterated	Piper Sandler	Overweight
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral
Oct-07-21	Initiated	Jefferies	Buy
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy
Nov-24-20	Resumed	Evercore ISI	Outperform
Nov-06-20	Reiterated	H.C. Wainwright	Buy
Jul-31-20	Initiated	Piper Sandler	Overweight
Jun-05-20	Initiated	BMO Capital Markets	Market Perform
May-05-20	Initiated	Chardan Capital Markets	Buy
Jan-30-20	Initiated	Canaccord Genuity	Buy
Jan-09-20	Upgrade	UBS	Neutral → Buy
Nov-07-19	Reiterated	H.C. Wainwright	Buy
Jun-25-19	Initiated	Stifel	Hold
Jun-10-19	Upgrade	B. Riley FBR	Neutral → Buy
Feb-28-19	Reiterated	H.C. Wainwright	Buy
Feb-22-19	Initiated	SVB Leerink	Outperform
Jan-23-19	Initiated	UBS	Neutral
Dec-14-18	Initiated	Wolfe Research	Outperform
Dec-12-18	Initiated	B. Riley FBR	Neutral
Nov-19-18	Downgrade	Raymond James	Mkt Perform → Underperform
Nov-16-18	Upgrade	Evercore ISI	In-line → Outperform
Sep-04-18	Initiated	Citigroup	Buy
Aug-06-18	Downgrade	Goldman	Buy → Neutral
Jun-28-18	Initiated	Raymond James	Mkt Perform

View All

Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News

Mar 25, 2026

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool

Mar 25, 2026

JPMorgan Chase & Co. Sells 8,030 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 25, 2026

Mar 23, 2026

Aug Selloffs: How correlated is Madrigal Pharmaceuticals Inc to the S P5002026 Price Momentum & AI Powered Market Trend Analysis - baoquankhu1.vn

Mar 23, 2026

Mar 22, 2026

Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge - MSN

Mar 22, 2026

Madrigal Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

Mar 20, 2026

Avoiding Lag: Real-Time Signals in (MDGL) Movement - Stock Traders Daily

Mar 20, 2026

Mar 19, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 19, 2026

Groupama Asset Managment Sells 13,447 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 19, 2026

MDGL Stock Price, Quote & Chart | MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) - ChartMill

Mar 19, 2026

Mar 17, 2026

2,600 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Bamco Inc. NY - MarketBeat

Mar 17, 2026

Mar 16, 2026

Iron Triangle Partners LP Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 16, 2026

First Light Asset Management LLC Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 16, 2026

Mar 15, 2026